Sangwoo Park

Chairman, CEO at NKMax America

Mr. Sangwoo Park is the founder and president of NKMax, a leading Korean biotech company that specializes in the development and manufacture of antibodies and proteins. Through Mr. Park’s vision and leadership, a first-in-kind in vitro diagnostic test, which measures NK cell activity using only 1 ml of blood, was commercialized. NKMax is now bringing its cutting-edge autologous and allogenic natural killer cell therapy to patients worldwide. Prior to founding NKMax, Mr. Park worked as a financial analyst at Samsung securities. Mr. Park earned his B.A. degree in economics from Korea University, Seoul Korea.


  • Chairman, CEO

    Current role

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.